THROMBOCYTOPENIA AS A RISK FACTOR FOR RETINOPATHY OF PREMATURITY.

Abstract

PURPOSE:

To study the association between thrombocytopenia and retinopathy of prematurity (ROP).

METHODS:

The case-control study was conducted on preterm newborns with ROP between January 2011 and January 2014, retrospectively. The patients were assigned into two groups: Cases required intervention and controls developed no or Stage I ROP.

RESULTS:

Eighty-one premature infants with Type I ROP were enrolled to the study with a mean gestational age of 27.6 ± 2.1 (range: 24-32) weeks and birth weight of 993 ± 292 (range: 560-1,930) g. Mean follow-up time was 38.3 ± 2.7 weeks (min: 32 and max: 46 weeks). Cases were individually matched to a set of controls (1:1 ratio). Thrombocytopenia (<150.000/mm) was seen in 58 (71.6%) of the cases with Type I ROP, whereas only 17 (21%) of the controls had thrombocytopenia (P < 0.001). Logistic regression analysis showed that bronchopulmonary dysplasia and thrombocytopenia were significantly associated with Type I ROP (relative risk [95% confidence interval]: 4.19 [1.47-12] and 6.69 [2.83-15.9], respectively). The thrombocytopenia ratio (P = 0.073), thrombocytopenia 1 week before intervention (P = 0.076) and platelet transfusion ratio (P = 0.062) tended to be higher in Zone I ROP compared with Zone II ROP.

CONCLUSION:

In our study, there was a significant association between thrombocytopenia and Type I ROP.

• Authors: Selim Sancak, Handan H Toptan, Tulin Gokmen Yildirim, Guner Karatekin, Fahri Ovali
• Journal: Retina (Philadelphia, Pa.) (Retina) Vol. 39 Issue 4 Pg. 706-711 (Apr 2019) ISSN: 1539-2864 [Electronic] United States
• PMID: 29370028 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Bevacizumab (therapeutic use)
• Birth Weight
• Case-Control Studies
• Female
• Gestational Age
• Humans
• Infant, Newborn
• Infant, Premature
• Intravitreal Injections
• Laser Coagulation
• Male
• Retinopathy of Prematurity (diagnosis, epidemiology, therapy)
• Retrospective Studies
• Risk Factors
• Thrombocytopenia (diagnosis, epidemiology, therapy)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)